Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
waveLINE-010: zilovertamab vedotin + R-CHP versus R-CHOP in previously untreated DLBCL
MOH_2024-12-08_013703Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zilovertamab vedotin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Started Dec 2024; status: recruiting.
02
Drugs
zilovertamab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2024-12-08_013703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-12-08_013703.